Letaplimab represents a novel medical approach for managing complement-mediated conditions. This biologic targets the C1q protein, a essential component of the complement pathway, aiming to disrupt its early https://kaleqvhb965734.activoblog.com/51551882/letaplimab-a-innovative-therapeutic-strategy